Trial Profile
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2021
Price :
$35
*
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SOTA-BONE
- Sponsors Lexicon Pharmaceuticals; Sanofi
- 03 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 20 May 2020 Planned End Date changed from 1 Dec 2020 to 30 May 2020.
- 12 Dec 2018 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.